It will be 60 days before this FDA Regulatory "draft" is
It will be 60 days before this FDA Regulatory "draft" is published which will only begin public debate and comment. I don't think FDA regulation would begin, if it ever does, for quite some time after the 60 days. Congress will also have to weigh in on it. I think LymPro will already be commercialized before any proposed regulation would begin.
The U.S. Government is spending so much money on Alzheimer's Disease through medicare already, and with the baby boomers entering their 70's soon, the cost is only going to skyrocket. LymPro will most likely already be in use by most Pharmas doing AD clinical trials before this proposed regulation ever takes effect. I doubt very much whether the FDA is going to stop these Pharmas from using Lympro if they say it is helping them find a cure for AD. If anything, if regulation comes in a year or two it might effect our future competitors who are a couple years behind us, more than it will effect us.
Plus, a year from now LymPro will have tested so many people under CLIA that they will be knocking at the FDA's door for out right FDA approval!! And I think Big Pharma doing AD clinical trials will be putting pressure on the FDA to do it. The sooner LymPro gains FDA approval and reimbursement the sooner the cost will go down from $1,500 to $1,000 and then down to $500. That will make it less expensive for Big Pharma to find AD cures.
So while anything is possible, I think it is very unlikely that this proposal will materialize soon enough to derail LymPro's launch or effect it's 2015 & 2016 CLIA revenue.
The bashers and flippers are out in full force using everything they can think of to cast a cloud of doubt over LymPro. I'm not buying it. The data presented Thursday was fantastic! AMBS will learn to communicate to non-scientists in the very near future. They've learned their lesson about speaking over their shareholder's heads. But there is nothing wrong with Lympro and it is on track to commercialize by November or December.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....
Continue Reading
A Second Shot with Electric Dreams Miguel Pantoja, once on the rocky road of life choices, now lights up Northern California with his spark — quite literally. Walking out of federal prison, his mind was set as firmly as a bolt: first stop was a burger, second was a plan to transform his past into a new beginning. That path took him to UEI College in Sacramento, where...
Continue Reading
An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...
Continue Reading
An Unexpected Turn in the UBI Movement In a world where tech and economic security must dance together, minding the steps is crucial. And this time, Amy Wilson's got her dancing shoes on. On September 24, 2026, the Income To Support All (ITSA) Foundation made some waves by adding Wilson to its board of directors, a move showing they're more serious than ever about...
Continue Reading
Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...
Continue Reading
Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....
Continue Reading
In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...
Continue Reading
Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...
Continue Reading
A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...
Continue Reading
illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...
Continue Reading
Top 5 Most Recently Viewed Articles
Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...
Continue Reading
Abeona Therapeutics Grants Equity Awards to New Employees Abeona Therapeutics Inc. (Nasdaq: ABEO), a burgeoning name in the biopharmaceutical landscape, has recently taken significant strides by granting equity awards to new non-executive staff members joining the Company. This move underscores Abeona's commitment to fostering a thriving work environment while navigating...
Continue Reading
Synchrony Financial Announces Dividends for Investors Synchrony Financial (NYSE: SYF), a leading player in consumer financial services, recently made a notable announcement regarding dividends for both its common and preferred stock. This declaration underscores the company’s commitment to delivering value to its shareholders. With a market capitalization of $27.1...
Continue Reading
Microchip Technology Launches Affordable PolarFire Core Solutions In today's competitive marketplace, the escalating costs of materials create challenges for developers seeking optimal performance while sticking to tighter budgets. Microchip Technology (NASDAQ: MCHP) has recognized the need for a cost-effective solution in the field of mid-range Field-Programmable Gate...
Continue Reading
Television Market Outlook: Significant Growth by 2029 Global television markets are on the rise, with projections indicating growth of approximately USD 73.1 billion from 2025 to 2029. This resurgence is spurred predominantly by innovation and the premiumization of products, setting the stage for accelerated market expansion. The market anticipates a compound annual...
Continue Reading
